How to use post-filing experimental data to help establish sufficiency and support

The Intellectual Property Laws Amendment (Raising the Bar) Act 2012 was introduced in Australia with the intention of aligning Australia’s written description requirements with those in the UK and Europe. Under the new Act, a specification must disclose the invention in a manner which is clear enough and complete enough for the invention to be

The matter with added matter in patent specifications – Allowability of amendments under post ‘Raising the Bar’ test

In the recent decision, CSIRO v BASF Plant Science GmbH [2020] FCA 328, the Federal Court of Australia considered the allowability of amendments to patent specifications under s 102(1) of the Patents Act 1990, as amended by the ‘Raising the Bar’ Act[1]. In overturning a decision of the Commissioner of Patents, Beach J decided that

Has “Raising the Bar” actually raised the bar on inventive step?

Nearly four years ago, on 15 April 2013, Australian patent law entered a brave new world.  Gone were the days of so-called “soft” patentability criteria that were out of kilter with those of our major trading partners – the Raising the Bar Act was going to change all of that.  One reputedly soft criterion was

The requirements of disclosure and support in Australian patent specifications post ‘Raising the Bar’

The Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (the RTB Act) commenced on 15 April 2013, and with it came a raft of changes to Australian patent law. Some of the most significant changes were intended to set higher thresholds for the level of disclosure and support required in a patent specification. In

Three strikes, you’re out: Rosuvastatin generics in the clear

The High Court of Australia handed down its decision yesterday in the appeal by AstraZeneca (AstraZeneca AB v Apotex Pty Ltd (2015) HCA 30), against last year’s ruling by the Full Court of the Federal Court,  affirming the Full Court’s decision that AstraZeneca’s low dose rosuvastatin patent was obvious.   The High Court has unanimously

Death of the ‘starting point’ approach: AstraZeneca v Apotex

A recent decision of the Full Court of the Federal Court of Australia, AstraZeneca AB v Apotex Pty Ltd (2014) 312 ALR 1 (‘AstraZeneca’) has clarified the tests for novelty and inventive step under the Patents Act 1990 (Cth). In relation to inventive step, the Full Court in AstraZeneca marked its disapproval of the ‘starting

Page 1 of 3123